GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » Total Current Liabilities

IMNM (Immunome) Total Current Liabilities : $54.31 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Immunome Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Immunome's total current liabilities for the quarter that ended in Dec. 2024 was $54.31

Immunome Total Current Liabilities Historical Data

The historical data trend for Immunome's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunome Total Current Liabilities Chart

Immunome Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Liabilities
Get a 7-Day Free Trial 3.04 9.73 7.33 21.83 54.31

Immunome Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.83 30.77 39.90 39.53 54.31

Immunome Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Immunome's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=39.307+0.063
+Other Current Liabilities+Current Deferred Liabilities
=7.996+6.941
=54.31

Immunome's Total Current Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=39.307+0.063
+Other Current Liabilities+Current Deferred Liabilities
=7.996+6.941
=54.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Immunome Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Immunome's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunome Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » Total Current Liabilities
Comparable Companies
BCYC GHRS PRTA SION NUVB CVAC PHVS COGT ABCL AVXL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011
Website
https://www.immunome.com
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
Executives
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Robert Lechleider officer: Chief Medical Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett officer: SVP Operations C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Jean Jacques Bienaime director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Higgins officer: Chief Scientific Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas director, other: See remarks 1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner officer: Chief Strategy Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson officer: Chief Technology Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp director, 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast director
Michael Lefenfeld director IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma director, officer: President and CEO IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim director 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019